153 related articles for article (PubMed ID: 3496938)
1. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF.
Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH
Brain Res; 1987 Jul; 415(2):293-9. PubMed ID: 3496938
[TBL] [Abstract][Full Text] [Related]
2. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum.
Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH
Life Sci; 1987 Jan; 40(2):193-202. PubMed ID: 3491946
[TBL] [Abstract][Full Text] [Related]
3. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice.
Heikkila RE; Cabbat FS; Manzino L; Duvoisin RC
Neuropharmacology; 1984 Jun; 23(6):711-3. PubMed ID: 6611514
[TBL] [Abstract][Full Text] [Related]
4. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Sirinathsinghji DJ; Whittington PE; Audsley AR
Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361
[TBL] [Abstract][Full Text] [Related]
5. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
[TBL] [Abstract][Full Text] [Related]
6. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
Pifl C; Schingnitz G; Hornykiewicz O
Neurosci Lett; 1988 Oct; 92(2):228-33. PubMed ID: 3263594
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Di Paolo T; Bédard P; Daigle M; Boucher R
Brain Res; 1986 Aug; 379(2):286-93. PubMed ID: 2427166
[TBL] [Abstract][Full Text] [Related]
8. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
Sershen H; Hashim A; Lajtha A
Pharmacol Biochem Behav; 1987 Oct; 28(2):299-303. PubMed ID: 3500479
[TBL] [Abstract][Full Text] [Related]
9. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration.
Pérez-Otaño I; Oset C; Luquin MR; Herrero MT; Obeso JA; Del Río J
Neurosci Lett; 1994 Jul; 175(1-2):121-5. PubMed ID: 7970192
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions.
Elsworth JD; Deutch AY; Redmond DE; Taylor JR; Sladek JR; Roth RH
Neuroscience; 1989; 33(2):323-31. PubMed ID: 2622529
[TBL] [Abstract][Full Text] [Related]
11. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys.
Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH
Brain Res; 1990 Apr; 513(2):320-4. PubMed ID: 2350702
[TBL] [Abstract][Full Text] [Related]
12. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
Bradbury AJ; Costall B; Domeney AM; Testa B; Jenner PG; Marsden CD; Naylor RJ
Neurosci Lett; 1985 Oct; 61(1-2):121-6. PubMed ID: 2417166
[TBL] [Abstract][Full Text] [Related]
13. Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse.
Perry TL; Yong VW; Jones K; Wall RA; Clavier RM; Foulks JG; Wright JM
Neurosci Lett; 1985 Aug; 58(3):321-6. PubMed ID: 3876525
[TBL] [Abstract][Full Text] [Related]
14. Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Pifl C; Bertel O; Schingnitz G; Hornykiewicz O
Neurochem Int; 1990; 17(2):263-70. PubMed ID: 20504626
[TBL] [Abstract][Full Text] [Related]
15. The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice. Antagonism by monoamine oxidase inhibitors.
Bradbury AJ; Costall B; Jenner PG; Kelly ME; Marsden CD; Naylor RJ
Neuropharmacology; 1986 Aug; 25(8):897-904. PubMed ID: 3022182
[TBL] [Abstract][Full Text] [Related]
16. Increase of striatal dopamine turnover by stress in MPTP-treated mice.
Urakami K; Masaki N; Shimoda K; Nishikawa S; Takahashi K
Clin Neuropharmacol; 1988 Aug; 11(4):360-8. PubMed ID: 3264755
[TBL] [Abstract][Full Text] [Related]
17. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
Neurosci Lett; 1985 Oct; 61(1-2):195-200. PubMed ID: 3878482
[TBL] [Abstract][Full Text] [Related]
18. Behavioral and biochemical changes following acute administration of MPTP and MPP+.
Tadano T; Satoh N; Sakuma I; Matsumura T; Kisara K; Arai Y; Kinemuchi H
Life Sci; 1987 Mar; 40(13):1309-18. PubMed ID: 2436017
[TBL] [Abstract][Full Text] [Related]
19. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
Sirinathsinghji DJ; Heavens RP; McBride CS
Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784
[TBL] [Abstract][Full Text] [Related]
20. Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys.
Falardeau P; Bédard PJ; Di Paolo T
Neurosci Lett; 1988 Mar; 86(2):225-9. PubMed ID: 2966905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
